T-cell trafficking in asthma: Lipid mediators grease the way

Nature Reviews Immunology

Volumn 4, Issue 9, 2004, Pages 711-724

  Luster, Andrew D ^a   Tager, Andrew M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 5 HYDROPEROXY 6,8,11,14 ICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONIC ACID; CHEMOKINE RECEPTOR CCR7; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LEUKOTRIENE A4; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; LIPID; LIPOCALIN; OMALIZUMAB; PHOSPHOLIPASE A2; PROSTAGLANDIN D2; PROSTAGLANDIN H2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; RAMATROBAN; RANTES; S 5751; THROMBOXANE A2; UNCLASSIFIED DRUG; ZILEUTON;

ASTHMA; CELL MIGRATION; CELL TRANSPORT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; LUNG LAVAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH2 CELL;

ANIMALS; ASTHMA; CELL MOVEMENT; HUMANS; LEUKOTRIENE B4; LIPID METABOLISM; PROSTAGLANDIN D2; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LEUKOTRIENE B4; RECEPTORS, PROSTAGLANDIN; T-LYMPHOCYTES;

EID: 4544296118     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1438     Document Type: Review

References (118)

1. Busse, W. W. & Lemanske, R. F. Jr. Asthma. N. Engl. J. Med. 344, 350-362 (2001).
2. Wills-Karp, M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17, 255-281 (1999).
3. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875 (2001).
4. Peters-Golden, M. & Brock, T. G. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 487, 323-326 (2001).
5. Werz, O. 5-lipoxygenase: cellular biology and molecular pharmacology. Curr. Drug Targets Inflamm. Allergy 1, 23-44 (2002).
6. Peters-Golden, M. & Brock, T. G. 5-lipoxygenase and FLAP. Prostaglandins Leukot. Essent. Fatty Acids 69, 99-109 (2003).
7. Fabre, J. E. et al. Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J. Clin. Invest. 109, 1373-1380 (2002).
8. Kanaoka, Y & Urade, Y. Hematopoietic prostaglandin D synthase. Prostaglandins Leukot. Essent. Fatty Acids 69, 163-167 (2003).
9. Urade, Y. et al. Mast cells contain spleen-type prostaglandin D synthetase. J. Biol. Chem. 265, 371-375 (1990).
10. 2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J. Immunol. 143, 2982-2989 (1989).
11. 2 by human helper T cell subsets. J. Immunol. 164, 2277-2280 (2000).
12. 2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129, 1627-1631 (1982).
13. 2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J. Immunol. 133, 2138-2144 (1984).
14. Smith, M. J., Ford-Hutchinson, A. W. & Bray, M. A. Leukotriene B: a potential mediator of inflammation, J. Pharm. Pharmacol. 32, 517-518 (1980).
15. Ford-Hutchinson, A. W., Bray, M. A., Doig, M. V., Shipley, M. E. & Smith, M. J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286, 264-265 (1980).
16. 4. Proc. Natl Acad. Sci. USA 81, 3501-3505 (1984).
17. Leppert, D. et al. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J. 9, 1473-1481 (1995).
18. Bacon, K. B., Camp, R. D., Cunningham, F. M. & Woollard, P. M. Contrasting in vitro lymphocyte chemotactic activity of the hydroxyl enantiomers of 12-hydroxy-5,8,10,14-eicosatetraenoic acid. Br. J. Pharmacol. 95, 966-974 (1988).
19. 4 - an immunohistochemical study. Clin. Exp. Dematol. 17, 413-420 (1992).
20. 4 that mediates chemotaxis. Nature 387, 620-624 (1997).
21. 4 receptor expressed on eosinophils. J. Exp. Med. 188, 1063-1074 (1998).
22. 4-BLT1 pathway in the early recruitment of CD4+ and CD8+ T cells to the airways.
23. 4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nature Immunol. 4, 965-973 (2003).
24. 4 as the chemoattractant mediating the CD8+ effector T-cell migration that is induced by activated mast cells.
25. Manjunath, N. et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J. Clin. Invest. 108, 871-878 (2001).
26. Weninger, W., Crowley, M. A., Manjunath, N. & von Andrian, U. H. Migratory properties of naive, effector, and memory CD8+ T cells. J. Exp. Med. 194, 953-966 (2001).
27. H2 cells in vivo. J. Immunol. 162, 1278-1286 (1999).
28. H2 cells.
29. H and type 2 T cytotoxic cells in health and disease. Eur. J. Immunol. 30, 2972-2979 (2000).
30. Sallusto, F., Lenig, D., Mackay, C. R. & Lanzavecchia, A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187, 875-883 (1998).
31. H2s. J. Exp. Med. 187, 129-134 (1998).
32. H cells. J. Immunol. 161, 5111-5115 (1998).
33. 2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. J. Invest. Dermatol. 119, 609-616 (2002).
34. van der Heijden, F. L., Wierenga, E. A., Bos, J. D. & Kapsenberg, M. L. High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J. Invest. Dermatol. 97, 389-394 (1991).
35. Dahlen, S. E. et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl Acad. Sci. USA 78, 3887-3891 (1981).
36. Tonnesen, M. G. Neutrophil-endothelial cell interactions: mechanisms of neutrophil adherence to vascular endothelium. J. Invest. Dermatol. 93, 53S-58S (1989).
37. Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A. & Springer, T. A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 184, 1101-1109 (1996).
38. 4-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J. Exp. Med. 192, 439-446 (2000).
39. Gerszten, R. E. et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398, 718-723 (1999).
40. 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98, 1942-1948 (2001).
41. Henderson, W. R. et al. The importance of leukotrienes in airway inflammation in a mouse model of asthma. J. Exp. Med. 184, 1483-1494 (1996).
42. Turner, N. C. & Dollery, C. T. Release of arachidonic acid metabolites and histamine from sensitized guinea-pig lung following antigen challenge. Br. J. Pharmacol. 93, 751-758 (1988).
43. Walls, A. F. et al. Inflammatory mediators and cellular infiltration of the lungs in a guinea pig model of the late asthmatic reaction. Lung 169, 227-240 (1991).
44. Seymour, M. L. et al. Leukotriene and prostanoid pathway enzymes in bronchial biopsies of seasonal allergic asthmatics. Am. J. Respir. Crit. Care Med. 164, 2051-2056 (2001).
45. 4 synthase in asthmatic children. J. Asthma 40, 147-154 (2003).
46. 4 levels in the arterial blood of asthmatic patients and the effects of prednisolone. Eur. Respir. J. 8, 605-610 (1995).
47. Sampson, A. P., Castling, D. P., Green, C. P. & Price, J. F. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch. Dis. Child 73, 221-225 (1995).
48. Wenzel, S. E. et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am. J. Respir. Crit. Care Med. 152, 897-905 (1995).
49. 2 are involved in asthma attacks in children. J. Asthma 35, 445-448 (1998).
50. Csoma, Z. et al. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am. J. Respir. Crit. Care Med. 166, 1345-1349 (2002).
51. Montuschi, P. & Barnes, P. J. Exhaled leukotrienes and prostaglandins in asthma. J. Allergy Clin. Immunol. 109, 615-620 (2002).
52. Drazen, J. M. Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann. NY Acad. Sci. 524, 289-297 (1988).
53. Sehmi, R. et al. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 79, 2952-2959 (1992).
54. 4. J. Pharm. Pharmacol. 33, 616-617 (1981).
55. 4. Biochim. Biophys. Acta 803, 271-277 (1984).
56. Hebert, M. J., Takano, T., Holthofer, H. & Brady, H. R. Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. J. Immunol. 157, 3105-3115 (1996).
57. Fahy, J. V, Kim, K. W., Liu, J. & Boushey, H. A. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. 95, 843-852 (1995).
58. Lamblin, C. et al. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am. J. Respir. Crit. Care Med. 157, 394-402 (1998).
59. Sur, S. et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa?, Am. Rev. Respir. Dis. 148, 713-719 (1993).
60. Bousquet, J. et al. Eosinophilic inflammation in asthma. N. Engl. J. Med. 323, 1033-1039 (1990).
61. Leckie, M. J. et al. Effects of an interteukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356, 2144-2148 (2000).
62. 2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am. Rev. Respir. Dis. 142, 126-132 (1990).
63. Crea, A. E., Nakhosteen, J. A. & Lee, T. H. Mediator concentrations in bronchoalveolar lavage fluid of patients with mild asymptomatic bronchial asthma. Eur. Respir. J. 5, 190-195 (1992).
64. 2 into human airways during acute antigen challenge. N. Engl. J. Med. 315, 800-804 (1986).
65. Wenzel, S. E., Westcott, J. Y., Smith. H. R. & Larsen, G. L. Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am. Rev. Respir. Dis. 139, 450-457 (1989).
66. 2 in the long-lasting airways vasodilatation induced by allergen in the sensitized pig. Acta Physiol. Scand. 143, 93-103 (1991).
67. 2 in rat and human skin. Br. J. Pharmacol. 56, 229-233 (1976).
68. Marom, Z., Shelhamer, J. H. & Kaliner, M. Effects of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glycoproteins from human airways in vitro. J. Clin. Invest. 67, 1695-1702 (1981).
69. 2 in normal and asthmatic men. N. Engl. J. Med. 311, 209-213 (1984).
70. 2 potentiates airway responsiveness to histamine and methacholine. Am. Rev. Respir. Dis. 133, 252-254 (1986).
71. 2 causes accumulation of eosinophils in the lumen of the dog trachea. J. Appl. Physiol. 67, 959-962 (1989).
72. Oshiba, A. et al. Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific immunoglobulin (Ig) E and IgG1 in mice. J. Clin. Invest. 97, 1398-1408 (1996).
73. al-Laith, M. et al. Immunoglobulin-G-dependent stimulation of guinea pig lung mast cells and macrophages. Allergy 48, 608-614 (1993).
74. Paterson, N. A., Wasserman, S. I., Said, J. W. & Austen, K. F. Release of chemical mediators from partially purified human lung mast cells. J. Immunol. 117, 1356-1362 (1976).
75. 2 by immunologically activated rat intestinal mucosa mast cells. J. Immunol. 140,1953-1957 (1988).
76. Katz, H. R. et al. Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells. J. Immunol. 148, 868-871 (1992).
77. 4 production and lysosomal enzyme release by rat alveolar macrophages: effects of phagocytosis, receptor binding, and ionophore stimulation. Exp. Lung Res. 13, 385-399 (1987).
78. 4 in response to IgG stimulation. J. Clin. Invest 83, 1691-1700 (1989).
79. Brewer, J. P., Kisselgof, A. B. & Martin, T. R. Genetic variability in pulmonary physiological, cellular, and antibody responses to antigen in mice. Am. J. Respir. Crit. Care Med. 160, 1150-1156 (1999).
80. Hamid, Q., Tulic, M. K., Liu, M. C. & Moqbel, R. Inflammatory cells in asthma: mechanisms and implications for therapy. J. Allergy Clin. Immunol. 111, S5-S12 (2003).
81. Krump, E. & Borgeat, P. Kinetics of 5-lipoxygenase activation, arachidonic acid release, and leukotriene synthesis in human neutrophils: effects of granulocyte-macrophage colony-stimulating factor. Biochim. Biophys. Acta 1213, 135-139 (1994).
82. H2 cells early in allergic pulmonary inflammation.
83. Kung, T. T. et al. Mast cells modulate allergic pulmonary eosinophilia in mice. Am. J. Respir. Cell Mol. Biol. 12, 404-409 (1995).
84. Takeda, K. et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J. Exp. Med. 186, 449-454 (1997). References 83 and 84 examine allergic pulmonary inflammation in cKIT-deficient (W/Wv) mice, which have congenitally low numbers of tissue mast cells. Reference 83 shows reduced expression of the asthma phenotype in W/Wv mice after a single aeroallergen challenge, whereas reference 84 shows comparable expression of the asthma phenotype in W/Wv and wild-type mice after three airway antigen challenges. These data are consistent with the hypothesis that mast-cell-derived mediators have an important role in airway T-cell recruitment, specifically at early time points in active immunization models.
85. H2-cytokine levels, eosinophil recruitment mucus hypersecretion and hyper-responsiveness.
86. Pinzar, E. et al. Prostaglandin D synthase gene is involved in the regulation of non-rapid eye movement sleep. Proc. Natl Acad. Sci. USA 97, 4903-4907 (2000).
87. 2 in T-cell trafficking in active immunization asthma models.
88. H2 cells.
89. H2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 57, 173-177 (2002).
90. Lezcano-Meza, D., Negrete-Garcia, M. C., Dante-Escobedo, M. & Teran, L. M. The monocyte-derived chemokine is released in the bronchoalveolar lavage fluid of steady-state asthmatics. Allergy 58, 1125-1130 (2003).
91. Rothenberg, M. E., MacLean, J. A., Pearlman, E., Luster, A. D. & Leder, P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J. Exp. Med. 185, 785-790 (1997).
92. Gonzalo, J.-A. et al. Mouse monocyte-derived chemokine is invoked in airway hyperreactivity and lung inflammation. J. Immunol. 163, 403-411 (1999).
93. Chung, C. D. et al. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J. Immunol. 170, 581-587 (2003).
94. Humbles, A. A. et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc. Natl Acad. Sci. USA 99, 1479-1484 (2002).
95. -/- mice. FASEB J. 16, 1313-1315 (2002).
96. Goya, I. et al. Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. J. Immunol. 170, 2138-2146 (2003).
97. H2 cells and eosinophils to the airways.
98. Garcia-Zepeda, E. A. et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Med. 2, 449-456 (1996).
99. Mochizuki, M., Bartels, J., Mallet, A. I., Christophers, E. & Schroder, J. M. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J. Immunol. 160, 60-68 (1998).
100. H2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J. Immunol. 162, 2477-2487 (1999).
101. Shinkai, A. et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J. Immunol. 163, 1602-1610 (1999).
102. Zimmermann, N. et al. Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression. J. Immunol. 165, 5839-5846 (2000).
103. Matsukura, S. et al. Activation of eotaxin gene transcription by NF-κB and STAT6 in human airway epithelial cells. J. Immunol. 163, 6876-6883 (1999).
104. H2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J. Immunol. 165, 2205-2213 (2000).
105. Presta, L. G. et al. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623-2632 (1993).
106. Fahy, J. V. et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 155, 1828-1834 (1997). This report examines the effect that humanized mouse monoclonal antibody specific for the FcεR1-binding domain of human IgE has on allergic airway responses. It shows that treatment with IgE-specific antibody suppresses both the early- and late-phase responses to inhaled allergen in allergic asthmatic individuals.
107. Pauwels, R. The relationship between airway inflammation and bronchial hyperresponsiveness. Clin. Exp. Allergy 19, 395-398 (1989).
108. Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184-190 (2001).
109. Soler, M. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254-261 (2001). References 108 and 109 report the results of phase III, double-blinded, placebo-controlled trials of IgE-specific monoclonal antibody (omalizumab) treatment of patients with moderate-to-severe asthma who are dependent on inhaled corticosteroids. In both trials, treatment with IgE-specific antibody resulted in patients having significantly fewer asthma exacerbations, as well as being able to tolerate significant reductions in inhaled steroid doses.
110. 2 in acute and exercise-induced asthma in children. Clin. Exp. Allergy 28, 181-186 (1998).
111. Israel, E., Cohn, J., Dube, L. & Drazen, J. M. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 275, 931-936 (1996).
112. 4 antagonism in a primate model of asthma. J. Clin. Invest. 97, 381-387 (1996).
113. 4 receptor antagonist CP-105,696 in man following single oral administration. Br. J. Clin. Pharmacol. 45, 115-121 (1998).
114. 4 receptor antagonist. J. Pharmacol. Exp. Ther. 297, 468-466 (2001).
115. Stevenson, D. D. & Zuraw, B. L. Pathogenesis of aspirin-exacerbated respiratory disease. Clin. Rev. Allergy Immunol. 24, 169-188 (2003).
116. Arimura, A. et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J. Pharmacol. Exp. Ther. 298, 411-419 (2001).
117. 2-induced eosinophil migration in vitro. J. Pharmacol. Exp. Ther. 305, 347-352 (2003).
118. 2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest 109, 338-342 (1996).